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ABSTRACT: Subtype 2 serotonin (5-hydroxytryptamine, 5-HT) receptors are major
drug targets for schizophrenia, feeding disorders, perception, depression, migraines,
hypertension, anxiety, hallucinogens, and gastrointestinal dysfunctions.1 We report
here the predicted structure of 5-HT2B and 5-HT2C receptors bound to highly potent
and selective 5-HT2B antagonist PRX-08066 3, (pKi: 30 nM), including the key
binding residues [V103 (2.53), L132 (3.29), V190 (4.60), and L347 (6.58)] determin-
ing the selectivity of binding to 5-HT2B over 5-HT2A. We also report structures of the
endogenous agonist (5-HT) and a HT2B selective antagonist 2 (1-methyl-1-1,6,7,8-
tetrahydro-pyrrolo[2,3-g]quinoline-5-carboxylic acid pyridine-3-ylamide). We examine the
dynamics for the agonist- and antagonist-bound HT2B receptors in explicit membrane and water finding dramatically different
patterns of water migration into the NPxxY motif and the binding site that correlates with the stability of ionic locks in the D(E)RY
region.
’ INTRODUCTION
Three 5-HT2 receptors (2A, 2B, and 2C) are major drug
targets for schizophrenia, feeding disorders, perception, depres-
sion, migraines, hypertension, anxiety, hallucinogens, and gastro-
intestinal dysfunctions, but in many cases, it is desirable to bind
selectively to just one of these very similar receptors.1 These
5-HT2 receptors are highly homologous with ∼80% amino
acid identity in the transmembrane (TM) domain, so that
many 5-HT receptor antagonists (e.g., methylsergide, meter-
goline, mianserin, and ritanserin) have similar affinities for all
three 5-HT2 receptor subtypes.2 Unfortunately, there is a paucity
of antagonists selective for the 5-HT2B or 2C receptors, leading
to cross-selectivity for drugs targeting either receptor.
Previously, we reported the predicted the 3-dimensional (3D)
structure for human 5-HT2C receptors (hHT2CR) using the
MembStruk computational procedure.3 Based on this structure,
we used the MSCDock computational procedure to predict the
3D structures for bound ligand-protein complexes for agonists,
such as serotonin, and antagonists, such as ritanserin, metergo-
line, and methiothepin. The predicted structure-activity re-
lationship (SAR) data for a series of psilocybin analogs, both
agonists and antagonists, show a good agreement with the currently
known experimental data.
Here, we report the new predicted structures of human
5-HT2B receptors (hHT2BR) and hHT2CR using newer meth-
ods, the MembEnsemb and the GenMSCDock techniques. To
understand the subtype selectivity of hHT2BR and further drug
development of the HT2B selective antagonist, we used the
MembEnsemb (later version of the MembStruck) techniques to
predict the 3D structure for the hHT2BR and hHT2CR and the
GenMSCDock (later version of the MSCDock)3 techniques to
predict the binding site for both agonists (HT, SNF, RNF,
desmethylNF, ethylNF) and antagonists (SB-206533 derivatives,
PRX-08066), including some highly selective 5-HT2B antago-
nists known from the literature.
We report the predicted binding site and energies for five
known agonists and nine antagonists (Figures 1 and 2 and
Table 1), finding relative affinities that correlate well with
experiment. We also report the key residues in the binding site
that determine the selectivity of highly selective 5-HT2B ligands
Figure 1. The chemical structures of 5-HT2B receptor antagonists 1-3
and agonist 4.
Received: September 23, 2010
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binding to hHT2BR over hHT2AR/hHT2CR. The different
binding preferences of agonists vs antagonists were studied
through ensemble docking. Our molecular dynamics (MD)
studies in explicit lipids and water show ligand-induced
conformational changes, with the salt bridges in D(E)RY
motif maintained in antagonist dynamics but broken in
agonist dynamics. We observed that binding of the agonist
induce water to flow into the NPxxY region which seems to be
important in allowing the conformational transitions upon
activation.
’RESULTS
1. Structure Predictions of the 5-HT2B Structure. Over the
last two years, structures for two family human G protein-coupled
receptors (GPCRs) have been reported: human β2 adrenergic
(hβ2AR)4-6 and human A2A adenosine receptors (hAA2AR).
7
In addition the structures for turkeyβ1 (tβ1AR),8 bovine rhodopsin
(bRho),9-13 and opsin14,15 are available. Unfortunately, these struc-
tures include an inverse agonist or antagonist, providing little info-
rmation about the structures involved upon activation by agonist
binding.
The predicted seven TM regions for the three 5-HT2 recep-
tors are shown in Figure S1 in Supporting Information. Because
the experimental structures for some GPCRs show R-helical
extensions well beyond the surface of the membrane, we used a
standard secondary structure prediction (PSIPRED)16 method
to predict these extensions for the 5-HT2 receptors. These
extensions lead to an additional seven residues (EQRASKV) at
the cytoplasmic N-terminus of TM6, as shown by underlines in
Figure S1, Supporting Information. This includes the (D/E)RY
motif expected to be important in either stabilizing the inactive
state or facilitating activation.
1.1. TM Predictions. The seven TM regions of the 5-HT2B
receptor were first predicted by hydropathicity analysis and
information from sequence alignments. At ExPaSy home page,
a blast search on the query sequence [P41595, 5HT2B_HU-
MAN, 481 amino acids (a.a.) sequences] with NCBI BlastP
2.2.15 from UniProtKB Swiss-Prot DB (options; mammalian
and no fragment) was performed. After multiple sequence
alignment using the clustalW program, v.1.8.3, the TM regions
were predicted using three ways depending on the input
sequences: (i) a variety of protein sequences from other family;
(ii) only 5-HT family receptors; and (iii) individual TM
sequences. The following is the result of each case:
(i) TM prediction 1 using a variety of protein sequences: A
variety of 253 protein sequences from other GPCRs with
sequence identities from 18 to 98% was first generated. The
253 sequences included hydroxytryptammine, serotonin
receptor (HT), dopamine receptor (DR), adrenergic
receptor (AD), histamine (HR), trace amine-associated
receptor (TAA), cholecystokinin receptor (CCKAR),
gastrin precursor (GAST), muscarinic acetylcholine re-
ceptor (ACM), adenosine receptor (AA), neuromedin-U
receptor 2 (NMUR2) family receptors, displaying gaps in
TMs 1, 5, and 7. The second filtering generated total 118
sequences with identities from 18 to 98%, excluding
HRH1 receptor and filtering the species of human, rat,
and mouse to avoid the redundancy of gene sequence.
Total 118 sequences revealed gaps in TMs 1, 2, and 4.
Three passes were run, eliminating gap sequences until
the appropriate TM regions and hydrophobic centers
were yielded. Removing the sequences of AD and TAA
receptors, 91 sequences with 18-98% identity showed
gaps in only TM2. Further removing the sequences which
showed the bulge in TM2 (DRD1R, DRD5R, and
HT4R) and increasing the population of high or middle
sequence identity, final 46 sequences with 20-98%
identity successfully generated 7 TM regions without
any gaps in TM regions.
(ii) TM prediction 2 using the 5-HT receptor family: After
filtering out the non-5-HT receptor family from 46
sequences of TM prediction 1, a total of 29 sequences
were used for predicting 7 TM regions. The seven TM
regions and the hydrophobic centers without any gaps
were generated similarly.
(iii) TM prediction 3 using an individual TM as a query
sequence and a variety of protein sequences from the
other family as an input: Each TM region was decided
using an individual TM query sequence adding 4 to 6 a.a.
at the end of TM region from the result of TM prediction
1 (40 a.a. for TM1, 47 a.a for TM2, 40 a.a. for TMs 3 and
4, 41 a.a. for TM5, 42 a.a. for TM6, and 43 a.a. for TM7).
In each case, except TMs 4 and 6, the sequences with the
gaps were eliminated until the appropriate TM regions
and hydrophobic centers were yielded.
The comparison of all three TM predictions in Table S1,
Supporting Information, displayed that predicted TM 7 region
was exactly same among 3 methods. The other TM regions
had a good agreement within 1 up to 4 residue differences. The
hydrophobic centers also showed within 1 or 2 a.a. deviation.
Figure 2. The chemical structures of several SB-206533 1 derivatives.
The R5 lipophilic substituent is surrounded by the aliphatic environ-
ments (V3.33, L3.29, I4.56, V4.60, M5.39, and A5.46), while the R6
electron-withdrawing group is in the proximity of L3.29, S5.43, and
N6.55.
Table 1. Cavity Energy of Several SB-206533 1 Derivatives at
Human 5-HT2B and 2C Receptorsa
5-HT2B 5-HT2C
no. R5 R6 pKi unified cav pKi unified cav
46 SMe CF3 7.9 -47.53 8.6 -56.91
53 OiPr CF3 8.4 -51.39 8.5 -56.59
47 SEt CF3 8.0 -50.43 8.5 -55.19
48 SnPr CF3 7.8 -46.51 8.2 -54.57
56 SMe C2F5 7.5 -48.49 8.4 -54.09
36 tBu Cl 6.8 -41.67 7.7 -43.38
aThe compound was ordered by binding energy for 5-HT2C
receptors. Experimental data (pKi) were taken from ref 30; pKi,
5-HT2B: binding affinity (human cloned receptors, HEK 293 cells,
[3H]-5-HT); pKi, 5-HT2C: binding affinity (human cloned recep-
tors, HEK 293 cells, [3H]mesulergine); and unified cav: unified cavity E
(unit: kcals/mol).
422 dx.doi.org/10.1021/ci100375b |J. Chem. Inf. Model. 2011, 51, 420–433
Journal of Chemical Information and Modeling ARTICLE
However, the hydrophobic center of TM2 from TM prediction 2
revealed 10 residue differences.
To avoid the Pro problem in Helical Dynamics, four residues
LVLC before Pro were added to the N-terminal of TM3. To
study the ionic lock in DRY motif, two residues RA were
considered as a helix part of the beginning of TM4. In addition,
the 5-HT2B receptor was regenerated including EQRASKV at
the cytoplasmic part of TM6. These helix extensions of TMs 3, 4,
and 6 agreed well with the secondary structure prediction using
PSIPRED server16 which predicted those extensions as a helix
part, as shown in Figure S2, Supporting Information. The final
TM region of the 5-HT2B receptor was shown in Figure S3,
Supporting Information.
1.2. The Hydrophobic Centers (Peak vs Area Methods). In-
itially we chose the center of each TM region from a combination
of the middle of the predicted TM region modified by any
maximum in the hydrophobicity17,18 over this region. The peak
method finds the stable window which does not deviate 5 or
more from the value at window size 20 and average those stable
values. We also use the area method, the centroid of the
hydrophobicity area above the baseline, as an alternative method.
The area method bisects the area in the hydrophobic curve using
Metlab program.
In Table S2 in Supporting Information, hydrophobic centers
of the 5-HT2B receptor were compared in TM prediction 1-3.
In TM prediction 1, the hydrophobic center of TMs 2, 3, and 7
revealed around a 5, 2, and 2 residue difference between two
methods, respectively. In TM prediction 3, only TM2 displayed a
3.5 residue difference, and other TMs revealed similar centers.
Since the hydrophobic centers are important in the transla-
tional orientation of each individual helix, four structures of two
different hydrophobic centers (the peak and the area methods)
and energy scales (Eisenberg vs octanol) from Cartesian neutral
dynamics were generated for next step of PDB template genera-
tion and compared the protein packings.
1.3. PDB templates. For the generation of the 5-HT2B
structure, three PDB templates, frog rhodopsin (fRho),19 mouse
Mas-related gene (Mrg) C11 (mMrgC11),20 and human CCR1
(hCCR1) Chemokine receptor,21 were used. Each template
displayed different sequence identity of whole sequence with
the 5-HT2B receptor; 14% (17% in TM) for fRho, 13% (18% in
TM) for mMrgC11, and 17% (21% in TM) for hCCR1.21 Com-
pared to the structure generated by the fRho template, the root-
mean-square deviation (RMSD) of the 5-HT2B structure gen-
erated by mMrgC11 and hCCR1 receptor templates showed
3.44 and 3.98 Å, respectively, as shown in Figure S4, Supporting
Information. Major structural deviations are shown at the tilting
of upper TM5 in mMrgC11and the tilting of lower TM2 and
upper TM4 in hCCR1. Since the structure from mMrgC11
receptor displayed the similar structure with fRho, two structures
of the 5-HT2B receptor from fRho and hCCR1 template were
used for further steps.
Twominimized structures of the 5-HT2B receptors generated
by two different templates, fRho and hCCR1 receptors, were
compared. The MPSim energy suggested the 5-HT2B receptor
from fRho template displayed lower energywith∼60 kcal/mol than
that from hCCR1 template at the same rms force, 0.09 because of
better van derWaals (vdW) interaction. Thus, the 5-HT2B receptor
from fRho template was selected for the further study.
1.4. Secondary structure extension at TM6. To study the
interaction of ionic locks in DRY motif, an additional combina-
torial set with the extension of TM6 as an R-helix structure was
regenerated; -60 for TM1, 60 for TM2, 0 for TM3, 60 for
TM4,-30 and-60 for TM5, 30 and 60 for TM6, 0 and 30 for
TM7. Finally, the best 10 structures from 152 combinatorial sets
were minimized and compared by SCREAM total energy (Etot =
Tot-fm þ Tot-ScSc), total energy of charged (MinEtot,) and
neutral system (NeuEtot). Previous best structure (-60, -60,
0, 60, -30, 30, and -30) from new generated TM6 extended
structure showed all winners.
To select which hydrophobic centers and energy scale to use,
four structures of each receptor were analyzed for putative
binding sites and hydrogen-bonding (H-bonding) networks.
When compared H-bonding networks of TMs 1, 2, and 7
(N1.50, D2.50, N7.49) and TMs 2, 3, and 4 (S2.45, H3.42,
W4.50), the structure of the peak method and the octanol scale
displayed the best H-bonding networks which are conserved in
family A GPCRs, while the structure of the area method could not
mimic the classical H-bonding networks of TMs 2, 3, and 4 and
revealed unrealistic kinks at TM7. In addition, when compared the
orientation of the conserved residue in eachTM, rotation by octanol
scale gave better orientation than rotation by Eisenberg scale,
except TM2. Thus, the structure of the peak method and the
octanol scale was selected for further steps.
1.5. Helix scan. Hydrophobicity penalty decided the appro-
priate rotational range of hydrophobic scales within∼2 kcal/mol
energy difference for further interhelical energy scan in Figure S5,
Supporting Information. For example, in TM2, 0 to 90, -90
to-150 in blue line was selected. Other TMs were also chosen
by penalty E: 90 to -180 degree for TM1; 0 to -120/ 90 to
150 for TM3; all angles for TM4, 30 to -150 for TM5; 0
to-120 for TM6; and-30 to 30/ 180 for TM7. Interhelical
energy scans within 2 kcal/mol hydrophobicity penalty energy
difference using SCREAM22 yielded the optimal angles of
rotation for each helix.
Hydrophobicity penalty and interhelical energy scans in
Figure S6, Supporting Information yielded the optimal angles
of rotation for each helix to produce a combinatorial set of
hundreds of conformations. Three passes of combinations were
produced, yielding 144 different conformations, one of which is
to be selected as the best packing structure. For the first
combinatorial set (total: 128), two energetically favorable angles
for each helix were selected by SCREAM E1: 30 and -60 for
TM1; 0 and -150 for TM2; 0 and 150 for TM3; 30 and 60 for
TM4; 30 and -30 for TM5; 30 and 120 for TM6; and 30 and
180 for TM7, as shown in red ball. For the second combinatorial
set, 8 additional structures were generated: -60 for TM1; -30
for TM2; 0 and-30 for TM3; 30 and 60 for TM4;-30 for TM5;
30 for TM6; and 0 and 30 for TM7. For the third combinatorial
set, 8 additional structures were generated: -60 for TM1; -30
for TM2; 0 and-30 for TM3; 30 and 60 for TM4;-30 for TM5;
30 for TM6; and 0 and 30 for TM7.
Total 144 combinatorial sets were sorted by polar screamed E,
E1 (Totfmþ Totscsc-Vscsc- Cfsc- Intern), E2 (Totscsc-
Vscsc), and E3 (Totfm- Vtot- Intern). Since E3 best showed
the best packing structure, -60, 60, 0, 60, -30, 30, and -30
angles for each, the TM helix was chosen. However, E1 and E2
best structure (30, -150, 0, -60, -30, 120, 30) did not show
the classical H-bonding network of TMs 1-2-7, because the
orientation of the side chains of D2.50 and N1.50 directed
toward the membrane.
Finally, the hydrophobicity penalty and the interhelical energy
scans are to be re-examined for the best packing structure. Since two
more energetically favorable angles for 120 in TM1 and 90 in TM2
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were shown in the second MembScream, 4 more combinatorial sets
were generated and reordered byE1þ P*9, E2þ P*9, andE3þ P*9.
Current all 0 angles for all TM helixes were detected as an
energetically favorable helix orientation. In addition, the final best
structure revealed betterH-bonding networks of TMs 1, 2, and 7 and
TMs 2-4 as well as ligand binding compared with the beginning
structure before MembScream.
Figure S6, Supporting Information, shows the energetic for the
most stable 10 predicted conformations selected from a sequence
of optimizations.
For self-consistency, the best packing structure from Mem-
bEnsemb was re-examined using the recently developed BiHelix
method. BiHelix determines the optimum configuration by
sampling all combinations of the rotations of each of the 7
helices through 30 rotations, leading to (12)7 ∼ 35 million
conformations, for each of which the side chains are optimized
using SCREAM.21 To make this practical we evaluate ESCREAM
for each of the 144 helix pair combinations for each of the 12
nearest pairs of helices (1-2, 2-4, 4-5, 5-6, 6-7, 7-1, 3-1,
3-2, 3-4, 3-5, 3-6, and 3-7) to estimate the total energy for
the full 35 million 7-helix bundle conformational combinations.
We use the CombiHelix step to build the 1000 combinations
with the lowest estimated energy into explicit 7-helix bundles and
calculate the total energy after optimizing the side chains
(SCREAM). Then we select the best 100 using ESCREAM and
minimize for ∼10 steps using the DREIDING 3 force field
(FF).23 The best 20 of these bundles are then immersed in an
implicit membrane using a Poisson-Boltzmann model with
separate dielectric constants for the middle of the membrane,
the surface regions of the membrane, and the exterior. This
provides membrane solvation effects that disfavor helix rotations
exposing charged residues to inner part of the lipid bilayer.
1.6. The 5HT2C structure. To study the subtype selectivity, the
hHT2CR structure was mutated from the final best structure of
hHT2B receptor. All mutated side chains were reassigned by
SCREAM method. The lowest neutral energy angles for the
5-HT2B receptors were 15, 15, 0, -15, 15, 15, 0 for TM 1-7,
while the lowest energy angles for the 5-HT2C receptors were 0,
30, 0,-30, 0, 0,-30 for TM 1-7. The preferred angles for each
TM between two subtypes revealed (15 angle differences
among the subtypes. TM7 showed 30 angle deviation, while 0
is the best in TM3 in both cases.
Summarizing, we concluded that the best structure is the
one with the lowest total energy (MPSim E) based on the
hHT2BR (fRho template) using the peak hydrophobic center,
the Eisenberg hydrophobicity scale, and the Cartesian neutral
dynamics. The predicted best packing structure has the conforma-
tion {-60, 60, 0, 60,-60, 60, 0}with respect to the fRho template.
1.7. Bihelix/CombiHelix result. To validate the predicted
structure, Bihelix/CombiHelix was performed for the best pack-
ing structure. The Table S3, Supporting Information, shows the
top 10 structures out of ∼35 million from the BiHelix analysis.
The best packing structures from MembEnsemb (all 0 angles
correspond to the angles of-60, 60, 0, 60,-60, 60, and 0 from
MembEnsemb) rank as number 2 by total E. The best one differs
by a-30 rotation of TM4. The top 10 from the 1000 structures
of CombiHelix built explicitly are shown in Table 2. We find that
the all 0 structures lead to the best total E. We also find low-lying
structures with (30 variations of TMs 4, 6, and 7.
This final predicted 3D structure of the hHT2BR possesses the
H-bonding network found in the other known class A GPCR
structures.
In the middle of TM, D2.50 forms a hydrogen bond (HB) to
N1.50.
H3.42 forms a HB with S2.45 and with W4.50.
In the expected ligand binding site of the apoprotein, we find a
HB between D135 and Y370 (both are highly conserved within
biogenic amine receptors). We find that the predicted hHT2BR
structure leads to an ionic lock involving the (D/E)RY motif.
Thus we find two salt bridges between D152 (3.49) and R169
(4.39) and between R153 (3.50) and E253 (6.30) on the
cytoplasmic end. These ionic bonds are consistent with two
experiments;
The E6.30R mutation shows a highly constitutively active
receptor with enhanced affinity for agonist through disruption of
ionic interaction.24
R4.39E displays constitutively active arrestin mutant, stabiliz-
ing the agonist high-affinity state.25
2. Predicted Structures for hHT2BR Ligands. First, we
docked the rigid SB-206533 1, 5-methyl-1-3,5-dihydro-2H-
pyrrolo[2,3-f]indole-1-carboxylic acid pyridine-3-ylamide, (Figure 1).
This has >100-fold selectivity in binding to 5-HT2Bover 5-HT2A and
other receptors, which was based on the first selective pyridyl urea
5-HT2C/2B antagonist, SB-200646A.26 Then we studied another
conformational restricted analogue 2 (1-methyl-1-1,6,7,8-tetrahydro-
pyrrolo[2,3-g]quinoline-5-carboxylic acid pyridine-3-ylamide)
through the introduction of a six-membered ring, which is clearly
detrimental to 5-HT2C receptor affinity (pA2, 5-HT2B: 7.27 vs
pKi, 5-HT2C: 5.39).27
In addition, we predicted the binding site of PRX-08066 3
(Figure 1) from EPIX pharmaceutical company known to be a
highly potent (Ki ∼ 1.7 nM) and selective 5-HT2B antagonist
(Ki > 100 fold for more than 55 receptors tested).28 It (pKi,
hHT2B: 30 nM) has good bioavailability, preclinical safety
profile, and a low order of acute toxicity, which is under phase
II clinical trials for the treatment of pulmonary hypertension and
hypoxia-induced pulmonary hypertension syndromes.
Receptor modeling studies of the 5-HT2C receptor suggested
that the observed selectivity of 5-HT2B/2C receptors in SB-
206533 1 was expected from two valines, V212 and V608, of
which the corresponding amino acids were Leu in the 5-HT2A
sequence, thus constricting the pocket.29 However, little is
known about the selectivity between 5-HT2B and 2C receptors.
Here, we report the predicted binding site and energies for five
known agonists and nine antagonists (Figures 1and 2 and
Table 1), finding relative affinities that correlate well with experi-
ment. We also report the key residues in the binding site which
Table 2. The Best 10 Most Stable Packing Structures of the
Human 5-HT2B Receptor from CombiScream Analysisa
no. H1 H2 H3 H4 H5 H6 H7 ScreamTot MembSolE total E
1 0 0 0 0 0 0 0 605.0 -97.6 507.4
2 0 0 0 330 0 0 0 679.5 -101.0 578.5
3 0 0 0 0 0 30 0 693.9 -102.9 591.0
4 0 0 0 0 0 30 330 694.3 -96.7 597.6
5 0 0 0 0 0 0 330 708.0 -99.8 608.2
6 210 0 0 0 0 0 0 737.4 -96.8 640.6
7 0 0 0 0 0 30 300 746.3 -89.6 656.7
8 0 0 0 30 0 0 0 755.3 -93.5 661.8
9 0 0 0 120 0 0 0 739.9 -76.1 663.8
10 0 0 270 0 0 0 0 744.6 -76.1 668.5
aTotal energy (kcal/mol) = ScreamTot þ MembSolE.
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determines the selectivity of the hHT2BR over the 5-HT2A/2C
receptor through the docking study of highly selective 5-HT2B
ligands.
2.1. Selective hHT2BR Agonist 4 (SNF). Site-directed muta-
genesis, binding studies, ligand docking, and molecular dynamics
(MD) simulations suggest that terminal methyl groups of V103
in the hHT2BR form stabilizing vdW interactions with the
R-methyl group of SNF.1 The role of V103 in SNF binding to
5-HT2 receptors was subtype selective. Our predicted structure
agrees with the experimental data in the reported literature.1 The
protonated amine nitrogen of SNF 4 shows an ionic interaction
at conserved D135 in the biogenic amine receptor. An additional
vdW interaction between theR-methyl group carbon of SNF and
the terminalγ-methyl carbon of V103 stabilizes the complex with
3.79 Å distances, as shown in Figure 3.
To validate our model, we studied the stereoselectivity using
the other isomer. We find that the (R)-enantiomer of norfenflur-
amine binds in the same orientation as SNF, with amajor anchoring
interaction at D135. However, the R-methyl group of RNF is away
from the terminal γ-methyl carbon of V103 by 5.96 Å, missing
favorable vdW interactions in Figure 3. We find that des-
methylNF also has no vdW interaction at V103 because of the
absence of the methyl group. We find that ethylNF has unfavor-
able vdW interaction with the β-methyl carbon of the terminal
ethyl carbon. The V103L mutation has little effect on 5-HT
affinity, while the V103L mutation markedly and uniquely affects
SNF binding to hHT2BRs.1 Compared with SNF (-25.87 kcal/
mol in neutral cavity E), the binding E indicates that RNF,
DesMeNF, and EthylNF have a higher binding by 0.32, 0.45, and
2.92 kcal/mol (see Table S2, Supporting Information). There-
fore, we predict that SNF is the strongest binder at 5-HT2BR,
consistent with the experimental binding affinities (SNF >
DesmethylNF > RNF > EthylNF).1
2.2. Selective hHT2BR Antagonist 1 (SB-206553) and 2. We
docked the nonselective 5-HT2B/2C receptor antagonist, SB-
206533 1, to both of the hHT2BR and hHT2CR, as shown in
Figure S7A and B, Supporting Information. Common HB
interactions were found between the ureido-CO group and
the Ser-OH side chain at conserved S139 among 5-HT2 family
receptor. Comparing the cavity analysis, similar nonbonding E is
shown at the hHT2BR and at the 5-HT2C receptor. Additional
hydrophobic interactions stabilize the complex at conserved
residues, V136, F274 (2B)/ F272 (2C), and F299/F298. The
N-methyl of the cyclopenta-indole ring interacts with the
Figure 3. The binding site of the 5-HT2B receptor agonist, SNF 4, RNF, DesMeNF, and EthylNF.
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subtype variable residues, L132, I186, and V190 in the hHT2BRs
with nonbond energies of -2.48, -0.10, and -0.76 kcal/mol,
respectively. The corresponding amino acids at the 5-HT2C
receptors, I132, V186, and I190, also have favorable interaction
with nonbond energies. Thus, SB-206533 1 at the 5-HT2B and 2C
receptor shows similar total cavity E, -42.48 and -42.28 kcal/
mol, respectively. In addition, subtype-selective residues also reveal
similar interaction in Table S4, Supporting Information.
We predict that the 5-HT2B selective antagonist 2 in Figure
S7C and D, Supporting Information. The ureido-CO group has
a major HB interaction with Ser-OH at conserved S139,
stabilizing hydrophobic interactions with surrounding hydro-
phobic residues at conserved residues, V136, F274, and F299.
We predict that the major reason for reduced interaction at the
HT2C receptor is bad contacts at I132, which has unfavorable
vdW interaction (þ6.24 kcal/mol), compared with the favorable
vdW interaction at the hHT2BR (-2.32 kcal/mol), making
binding at the 5-HT2C receptor unfavorable byþ8.46 kcal/mol.
Other subtype selective residues, V190/I190 in 2C, L281/S279
in 2C, showed similar binding energetic. Consistent with experi-
ment, we find favorable interaction at HT2BR (-47.53 kcal/
mol), while binding to the HT2CR is þ11.47 kcal/mol less
favorable (Table S4, Supporting Information). Figure 4 super-
imposes 1 and 2, showing that the N-methyl of the cyclohexa-
indole ring of 2 is closer to the upper TM3 leading to unfavorable
interactions with the bulkier Ile side chain in 5-HT2CR (I132),
while the methyl of the cyclopenta-indole ring in 1 points toward
the upper TM 4. In addition, the cyclohexa-indole ring is
bordered by hydrophobic L281 in hHT2BR, while it is near
the hydrophilic residue S279 in the 5-HT2CR.
Further structure-activity relationship (SAR) studies were
used to validate the current binding mode.30 Based on the experi-
mental SAR in Table 1, the lipophilic group at R5 position and
the electron-withdrawing group at the 6 position were optimized.
Our predicted energies correlate well with the experimental
binding affinity at 5-HT2BR/2CR, with correlation coefficient
(r2 value) between experimental binding affinities (Pki) and the
calculated cavity E of 0.83 and 0.91 at the human 5-HT2B and 2C
receptors, respectively. We find that the R5 lipophilic substituent
is bordered by an aliphatic environments (V3.33, L3.29, I4.56,
V4.60, M5.39, and A5.46), while R6 has electron-withdrawing
group is in the proximity of L3.29, S5.46, and N6.55 (Figure 2).
2.3. Highly selective hHT2BR antagonist, 3 (PRX-08066). To
obtain a better understanding of the molecular basis of the
subtype selectivity of highly potent and selective hHT2BR
antagonist 3, we dock this ligand (see Figure 5 and Figure S8,
Supporting Information). We find that D135/D134 in TM3
(2B/2C) have a common salt bridge with a protonated amine in
pyridine ring (-7.52 for 2B vs -7.70 for 2C). We find that the
N atom of the thienopyrimidine ring makes an additional HB
with the side chain NH of N344/N311 in TM6. We find that
several hydrophobic residues stabilized the complex through
vdW interaction; the cyano group with V103/V102 and
the thienopyrimidine ring with F274/F272, L132/I132, and
Figure 4. Superimposition of the nonselective 5-HT2B/2C receptor antagonist (SB-206533 1) and the selective 5-HT2B receptor antagonist (2) at the
human 5-HT2B receptor. The N-methyl of the cyclohexa indole ring of 2 is closer to the upper part of TM3 leading to unfavorable interactions with
bulkier Ile side chains in the 5-HT2C receptors (I132), while themethyl of the cyclopenta-indole ring in SB-206533 1 is pointing toward the upper TM4.
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V190/I190 (Table S5, Supporting Information). We predict
that the binding is 24.27 kcal/mol more favorable interaction
at 5HT2BR compared to 5HT2CR supports, consistent with
experiment.
To learn more about subtype selectivity, we examined the
effect of mutations in the 5-HT2 receptors on binding of
antagonist 3 based on the multiple alignment of 11 serotonin
receptors in Figure S9, Supporting Information. Here we exam-
inedmutations at L132, L347, V103,M218, V190, and S372, in the
TM regions and K211, T210, and E212 in extracellular loop (EL)
2. Each residue was mutated into all 20 a.a., and the side chains
reoptimized. Thenwematch the ligand to the new binding site and
minimized the E for each mutant. We found that all mutations
decreased the affinity of 3. Thus the mutant L132I to mimic
5-HT2A/2C receptors revealed major decreased interactions by
6.8 kcal/mol compared with the wild-type (see Figure S10,
Supporting Information), supporting the direct role of this
residue in the selectivity of 3. Other mutants show that L347A
(2A) or S (2C), L347A (2A), V103L (2A), M218 V (2A/2C),
V190I (2A/2C), and S372C (2C) also lead to small decreased
interactions by 2.1, 3.4, 4.2, 0.3, 0.7, and 0.5 kcal/mol, respec-
tively. Mutations in EL2, K211D (2A/2C), T210A (2A) or N
(2C), and E212D (2A) or F (2C) have a negative effect,
decreasing binding by 1.1, 0.8, 0.8, 0.8, and 0.0 kcal/mol, but
little contribution to the selectivity of 3). These results show a
direct affect of mutations on affinity and selectivity. Our results
are consistent with reported mutational studies. Mutations at
V103 and A225 show that they play a role in the 2B/2C selec-
tivity.31 We propose additional mutation studies at residues,
L132, V190, and L347, to test our predictions that they are
involved in 5-HT2B/2C selectivity. For the 5-HT2B selective
ligands 2 and 3 studied, we found that the side chain at L132
directly determines relative ligand selectivity.
2.4. Docking of Endogenous Agonist, HT and Selective
Antagonist, 2 to Low-Lying Structures of 5-HT2B. To deter-
mine whether other low-lying structures of HT2B might play a
role in activation, we docked the endogenous agonist, 5-HT, and
selective antagonist 2, 5-HT2B, into the five lowest-lying packing
structures from the CombiHelix predictions in Table 2.
We find that agonist HT binds best to all 0 structures, but it
binds unfavorably to the structure with TM6 rotated by 30
(clock-wise from the extracellular view). This agonist binding
preference correlates with experimental data, suggesting that
binding agonist causes TM6 to rotates anticlockwise.32
However, we find that antagonist 2 prefers a slightly different
conformation, with TM7 rotated by-30, as shown in Table S6,
Supporting Information.
3. Dynamics. To study the effect of membrane and water on
the structures of the ligand-GPCR complex, we inserted the
predicted protein-ligand complexes into a periodic infinite
membrane fully solvated with water and carried out 10 ns of
MD at 300 K.
3.1. Apo-hHT2BR Dynamics. After 10 ns of MD, the major
change in the structure observed is a ∼ -20 rotation of TM 4.
We find that TM6 exhibits large variations with fluctuations
(28. However, the effective change of P6.50 position in TM6
compared to the starting structure is ∼ -10 rotation.
The following stable HB networks among TMs in the simula-
tion were shown in Apo-hHT2BR dynamics: N72 (1.50) and
D100 (2.50), the average heteroatom distance HB of 3.5 Å; S142
(3.39) and S307 (7.46), the average heteroatom distance of
3.2 Å; S142 (3.39) and N310 (7.49), the average heteroatom
distance of 3.3 Å.
In the binding site, we find that three HBs are stable: D135
(3.32) and Y304 (7.43), the average heteroatom distance of
3.7 Å; D135 (3.32) and W131 (3.28), the average heteroatom
distance of 3.6 Å; S139 (3.36) and W271 (6.48), the average
heteroatom distance of 2.9 Å.
In addition new HBs are formed in the cytoplasmic end: S150
(3.47) and Y314 (7.53) in the NPxxY region, the heteroatom
distance changes from 10.1 Å to 3.8 Å; and D152 (3.49) and
R153 (3.28) in the D(E)RY region, the heteroatom distance
changes from 11.9 Å to 3.8 Å.
3.2. Agonist (5-HT)-hHT2BR Dynamics. After 10 ns of MD,
the major change in the agonist (5-HT) bound structure is at TM
6 which rotates by ∼-80 (anticlockwise), which is consistent
with experiment.31 TM 6 also shows the largest fluctuations in
the average η angle by(55. The change in η difference is 7 for
N1.50 in TM1,-34 for D2.50 in TM2, 6 for D3.32 in TM3, 25
for W4.50 in TM4, -5 for P5.50 in TM5, -113 for P6.50 in
TM6, and 15 for P7.50 in TM7.
Interestingly, we found that all of the salt bridges in EL (E82-
K84, E82-K385, D152-R169, R153-E253, and E319-R321) and
IL (K193-D216, K211-D351, and R213-D351) in the agonist
(HT2)-hHTBR are unstable, breaking by 8 ns.
The following stable HB networks among TMs in the simula-
tion were shown in Agonist (5-HT)-hHT2BR dynamics: N72
(1.50) and D100 (2.50), the average heteroatom distance of
3.9 Å; S95 (2.45) and H145 (3.42), the average heteroatom
distance of 3.5 Å; and H145 (3.42) andW180 (4.50), the average
heteroatom distance of 3.0 Å
In the binding site, major anchoring interactions were stable:
D135 (3.32) and the protonated nitrogen, the average hetero-
atom distance of 3.5 Å; S139 (3.36) and the OH group, the
average heteroatom distance of 4.1 Å; and S222 (5.43) and the
NH group, the average heteroatom distance of 3.4 Å.
3.3. Antagonist (2)-hHT2BR simulations. After 10 ns of MD,
the major changes in the antagonist (2) bound structure a ∼120
rotation (clockwise) at TMs 6, unlike the agonist (5-HT)-hHT2BR.
However, the fluctuation of TM6 is(20. The average η difference
of N1.50, D2.50, D3.32,W4.50, P5.50, P6.50, and P7.50 is 16,-27,
-24, 15, 6, -20, and -1 angle. Compare to agonist (5-HT)-
hHT2BR, the rotations of TMs 3, 5, and 7 are opposite. Although
Figure 5. The predicted structure of the highly potent and selective
5-HT2B receptor antagonist PRX-08066 3.
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TM6 showed the same rotation, the change ismuch smaller (-20)
in the antagonist (2)-hHT2BR simulations compared to that of the
agonist (HT)-hHT2BR model (-113).
Major interactions in the binding site were stable: S139 and
the ureido-CO, the average heteroatom distance of 3.0 Å. The
ureido-CO group also revealed new weakH-bonding with 4.1 Å
average heteroatom distance of H-bonds at W337, which also
interacted with S139, resulting in final 2.9 Å heteroatom distance
of H-bonds after 10 ns.
Unlike the agonist-bound structure, we found that two salt
bridges between K211-D351 and between K193 and D216 in EL
relatively stable during the MD. Thus all three salt bridges in IL
(D152-R169, R153-E319, and E319-R321) are maintained.
With antagonist (2)-hHT2BR, we observed much less motion
of the ligand in the binding site, and there were no big differences in
the average backbone RMSD (BRMSD) of TM helices (∼ 2.0 Å
for all three cases). After 10 ns the RMS change in antagonist 2
was 1.0 Å (the average RMSD of 0.6 Å), while the RMS change
for agonist HT was 3.9 Å (the average RMSD of 3.1 Å). Thus
binding of agonist inducesmotion in the active site, while binding
of antagonist leads to a more rigid structure. This increased
rigidity of the antagonist (2)-hHT2BR system may block the
conformational change for constitutive activation.
The following stable HB networks among TMs in the simula-
tion were shown in Antagonist (2)-hHT2BR simulations: N72
(1.50) andD100 (2.50), the average heteroatom distance of 2.8 Å;
S95 (2.45) and H145 (3.42), the average heteroatom distance of
4.0 Å; D135 (3.32) and Y370 (7.43), the average heteroatom
distance of 3.1 Å; and S139 (3.36) and W271 (6.48), the average
heteroatom distance of 2.9 Å.
3.4. Water Channel from the Binding Site into the NPxxY
Motif. We observed water entering the conserved N1.50-D2.50-
N7.49 area (NPxxY region) during the MD for all three cases.
However just 2 waters moved into this region for the apo-hHT2BR,
compared to 6 for the antagonist complex and 14 for the agonist
complex. We found a common water path in the ligand-bound
system, as shown in Figure 6. Thus binding of agonist promotes
migration of water inside the protein, which facilitates the conforma-
tional change upon activation compared with the antagonist.
In the apo-hHT2BR-membrane complex, two waters are in
the NPxxY region (water within 5 Å of N1.50, D2.50, and N7.49
in VMD program). Thus by 1.7 ns, 2 water molecules in the
NPxxY region were observed in the water layer, passing through
the D(E)RY motif which was important for family A GPCR
activation, as shown in Figure 6.
Water in the proximity of D135 (3.32), which is the major
anchoring point with the protonated nitrogen, passed into S307
(7.46), S142 (3.39) into the NPxxY region. This phenomenon
suggests that ligand binding in the binding site might regulate the
conformational change at the NPxxY region through water.
In the antagonist (2)-bound hHT2BR, water in the proximity
of D135 or Y304 in the binding site enters into the NPxxY region,
forming HBs with D100, N310, S142, and S307.
In contrast the dynamics of agonist (5-HT)-bound hHT2BR
shows water in the proximity of N278 or Y304 in the binding site
penetrate into the NPxxY region, forming HBs with D100, S142,
and S307.Morewater in theNPxxY region is floating around in the
water pocket through alternative HBs with neighboring hydro-
philic residues, N72, D100, S142, S307, and N310. In particular,
W271, which is involved in thewater channel, is thought to control
the beginning of activation as a rotamer switch. One water near
R153 also can go intoN72. This means the possibility of the cross-
talk between the D(E)RY and the NPxxY regions.
The corresponding amino acids of S142 (3.39) and S307
(7.46) in bRho are the hydrophobic residues of Ala. Unlike bRho,
hHT2BR displays a constitutive basal activity.33 The hHT2BR
seems to provide more flexibility of the protein through the
alternative H-bond interactions at two additional hydrophilic
Figure 6. Water path (yellow arrow) of apoprotein, antagonist (2), and agonist (HT) bound 5HT2B receptor complexes during 10 ns dynamics in
explicit water andmembrane. Ligands andwater in the 5 Å proximity ofN172, D100, andN310 (NPxxY region) are displayed using a space-fillingmodel.
The structure was taken from last trajectory of 10 ns dynamics.
428 dx.doi.org/10.1021/ci100375b |J. Chem. Inf. Model. 2011, 51, 420–433
Journal of Chemical Information and Modeling ARTICLE
regions, S3.39 and S7.46, in the water channel. These additional
hydrophilic residues in the water channel extending from the
binding site to the NPxxY region correlate with the higher basal
activity or protein instability compared to bRho.
Explicit water mediates the H-bond between S222 and the
tryptophanNHgroup of agonist (5-HT) after 1 nsMD. After 9 ns,
preserved interactions in the binding site between protonated
nitrogen and D135 convert into water-mediated interactions.
3.5. Ionic Lock Stability in the D(E)RY Motif. For the apopro-
tein structure of hHT2BR, the ionic locks between R153 and
E253 and between D152 and R169 in the D(E)RY region
constrain the motions of helix 6 relative to 3:
(1) In apoprotein dynamics, the interaction between TMs 3
and 4 is stable, while the other salt bridge between TMs 3
and 6 is not stable, as shown in Figure 7. The first break
between R153 and E253 occurred at around 2 ns, but the
H-bond was reformed later. However after 6 ns, the
distance between two hetero atoms of the counter charge
increases with the final heteroatom distance of 9.1 Å,
while the other final heteroatom distance is 2.6 Å.
(2) In agonist (5-HT)-hHT2BR, both of the salt bridges are
broken after 6 and 8 ns. The interaction between R153
and E253 is first destabilized. Final distances between
R153 and E253 and between D152 and R169 were 13.2
and 9.8 Å, respectively. Supporting this, TMs 4 and 6
resulted in the high BRMSD in Figure 7.
(3) In the antagonist (2)-bound hHT2BR simulation, both
interactions were stabilized. Final distances between
R153 and E253 and between D152 and R169 were 3.1
and 2.5 Å, respectively.
These observations support the idea that the D(E)RY motif
plays an important role in protein activation.34 Thus, themotions
observed with respect to helix 4 and 6 provide a strong indication
that such changes are involved in protein activation.
’DISCUSSION AND CONCLUSIONS
The dynamics for the agonist-hHT2BR structure leading to
substantial migration of water into the NPxxY region, and the
breaking of the ionic lock suggests that binding of the agonist might
be able to cause activation of the GPCR. The second alternative is
that there might be two or more stable states of the receptor
(inactive state R and active state R* with the full agonists binding to
R*, while inverse agonists binding to and stabilizing R). Indeed
there is a growing body of experimental evidence for the existence
of multiple conformational states.35 Our results indicate that several
distinct conformations can bind to the agonist and the antagonist,
supporting the idea of multiple conformations.
Our ensemble docking result with several lower-lying packing
structures of hHT2BR from the BiHelix/CombiHelix method
revealed the different binding preference between an endogen-
ous agonist (5-HT) and a HT2B selective antagonist 2. The
antagonist 2 preferred to bind to the structures for which TM7
was rotated by-30. However, the agonist 5-HT revealed weak
interactions in the structures for which TM6 was rotated by
30 in the clockwise rotation from the extracellular view. The
Figure 7. Trajectory analysis of salt bridge interactions in the D(E)RY region (left), the final heteroatom distance of human 5-HT2B receptor
(hHT2BR) structures at 10 ns (middle), and the RMSD of backbone in each TM (right). Antagonist (2)-hHT2BR (top), apo-hHT2BR (middle), and
agonist (HT)-hHT2BR (bottom).
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predicted agonist binding preference is consistent with the
experimental data, the anticlockwise rotation of TM 6 from the
extracellular view.32
Examination of the MD trajectory indicates that antagonist-
hHT2BR simulations differ substantially from the dynamics of
the apo-hHT2BR and agonist-hHT2BR systems. Both of the two
salt bridges in the D(E)RY regions of the antagonist (2)-bound
hHT2BR simulation were relatively stable during the simulation,
while both interactions were broken in agonist (5-HT)-hHT2BR
after 6 and 8 ns, sequentially. Apo-dynamics display the inter-
mediate stability of these interactions. The interaction of TMs 3
and 4 is stable, but the other salt-bridge between TMs 3 and 6 is
not stable, as summarized in Figure 7.
In addition, the comparison of the dynamics of agonist and
antagonist-bound HT2BRs shows the high RMSD of agonist in
the binding site. The more flexible agonist in the binding site
allows more water inside the protein and forms a water channel
from the binding site to the loosely packed NPxxY region. This
region is believed to be important in allowing conformational
transitions as there will be fewer steric restraints to side chain
packing. Floating water in theNPxxY region is thought to act like a
buffer to reduce a steric clash or an electrostatic repulsion between
the same charges when the conformational change occurs.
As conclusions, the general agreement of the predicted
structures with experimental mutation and binding data suggests
that these methods of protein structure prediction are reasonably
accurate. Thus:
(1) The final best structure of the hHT2BR from MembEn-
semb and BiHelix leads to the ionic lock involving
(D/E)RY motif, and we expected TMs 1, 2, and 7 and
TMs 2-4 as networks of class A GPCRs.
(2) SNF as an agonist is the strongest binder at the hHT2BR
among four derivatives, consistent with their experimen-
tal binding affinity (SNF > DesmethylNF > RNF >
EthylNF).1 The cavity energies of 6 antagonists paral-
leled with the experimental binding affinities at the
hHT2BR and hHT2CR with the correlation coefficient
(r2) values of 0.83 and 0.91.
(3) Docking complex (2) suggests a novel binding interactions
for these series of diaryl ureas, involving a H-bonding
interaction between the urea carbonyl oxygen of the ligand
and S139 (3.36), which is unique at 5-HT2 family receptor.
(4) In the docking models of the 5-HT2B, selective antago-
nists 2 and 3 (PRX-08066), V103 (2.53), L132 (3.29),
V190 (4.60), A225 (5.46), and L347 (6.58) lead to
subtype selectivity among the 5-HT2 family receptors.
(5) The ensemble docking study with several lower-lying
packing structures reveals the different binding prefer-
ence of a full agonist (5-HT) and an antagonist (2).
(6) The simulations reveal that the salt bridges in D(E)RY
motif are maintained in antagonist dynamics but broken
in agonist dynamics. The NPxxY region filled with water
from the ligand binding site is believed to be important in
allowing the conformational transitions upon activation.
Thus, this modeling study will help to design more potent and
more selective drugs for the hHT2BRwithout undesired side effects.
’METHODS
1. Generation of the 5-HT2B Structure Using MembEn-
semb Program, v.4.30. First, the 3D structures of the hHT2BR
based only on its primary sequence were predicted using the
MembEnsemb first principles method, which was updated from
the Membstruk first principles method.36,37 All E and force cal-
culations used the DREIDING FF23 for the ligand and
CHARMM22 charges for the protein.38 The MembEnsemb
procedure involves the following steps.
1.1. Predict TM Region. Our method for predicting the seven
TM domains, PredicTM, which is developed from earlier version
of TM2ndS,36 uses hydropathicity analysis combined with infor-
mation from multiple sequence alignments. We start with about
50-200 sequences having sequence identities from the target
structure varying uniformly from 20 to 90%.
The second step of TM2ndS is to calculate the consensus
hydrophobicity for every residue position in the alignment using
the average hydrophobicity of all the amino acids in that position
over all the sequences in the multiple sequence alignment. Then,
we calculate the average hydrophobicity over a window size
(WS) of residues about every residue position, using WS ranging
from 12 to 30. The average hydrophobicity value at each
sequence position was plotted to yield the hydrophobic profile.
MembStruk procedure used the Eisenberg hydrophobicity scale,
but with MembEnsemb we now use eight different hydrophobi-
city scales: (1) thermodynamic hydrophobic octanol as a default;
(2) the interface of octanol; (3) the average of thermodynamic
and biological hydrophobic scales; (4) biological hydrophobic
scales; (5) hydrophobicity penalty with the solvent accessible
surface area developed by Jenelle; (6) the Eisenberg hydropho-
bicity (the scale used by the original TMPred); (7) newEisenberg;
and (8) interface.
1.2. Create PDB Template. The initial z position of each of the
7 helices and the initial orientation η, and the initial x and y
positions are taken from the 7.5 Å electron density map of
fRho,19 mMRgC11,20 and hCCR121 receptors, which was gen-
erated using TMPred.
In addition, the tilt (θ) of each axis from the z axis and the
azimuthal orientation (j) is taken from this structure. This is the
procedure used for previous applications of MembStruk. However,
for MembEnsemb, we are now extracting the x, y, θ, and j from
those predicted structures of GPCRs that have been successful in
predicting binding sites of known ligands and thosewhich have been
subjected to MD optimization with full membrane and solvent. We
will use one or more sets of x, y, θ. and j from this database as
starting points for the GPCRs being studied. After optimization,
the helix is reinserted in the bundle while preserving the major
axis, which is followed by a full bundle optimization.
With the predicted TM regions for the 5-HT2B/2C receptors,
the canonical helices were generated. The helical axes are
positioned according to each template, with the hydrophobic
centers on the same fitting plane.
1.3. Rotation by Phobic Face. The helices will be treated as
canonical and have all C-R carbon positions (the middle 15
residues around the hydrophobic center) projected on to the
plane that intersects the hydrophobic center and aligns the
smallest moment of inertial along the z-axis. Then all projected
C-R positions will be assigned their hydrophobic scalar according
to the hydrophobicity scale chosen, and the program will
determine the largest gap of the helix that does not face other
helices and look at the largest number summing the C-R
numbers over that gap. The middle of the gap containing the
largest sum of all C-Rwill become the hydrophobic moment, and
the helix will be rotated to move this position to 180 from the
center of the protein. The canonical helices for the predicted TM
segments of the 5-HT2B/2C receptors were rotated by octanol
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scale for better orientation of hydrophobic side chains facing
toward the membrane.
1.4. Helix Dynamics. The structures of the individual helices
were optimizedwithEminimization followed by 100 psNewton-
Euler inverse mass operator (Neimo) torsional dynamics39,40 and
Cartesian dynamicswith charged force field or neutralQeQ charge
at 300 K (NVT). This optimizes the bends and the kinks in each
helix due to the presence of Pro and Gly in some TM domains.
This is an important step as it is believed that the individual
helices interact with each other in the lipid bilayer during the
folding process and that by the start of this interhelical interaction
they would have assumed their native bent or straight helix
conformations. The presence of bent helices disallows many
rotational combinations when the helices interact with each
other.
The spatial orientation of the helices and helical bends and
kinks were optimized by individual helix dynamics. The Neimo
dynamics and the Cartesian charge dynamics produced severe
kinking and unraveling of TM 2, eliminating it as a feasible
option. The Cartesian neutral structure is feasible because there
is little unraveling and minor kinking caused by the presence of
Pro. All prior calculations were repeated using the different
hydrophobic center of the area method.
1.5. Rotation by Hydrophobic Moments. The initial orienta-
tion (η) of the helix about this axis is determined by calculating
the net hydrophobic moment of the middle one-third of the helix
(centered at the hydrophobic center) by counting only the half
circle that would be oriented toward the lipid. The calculation of
the hydrophobic moments uses only the middle 15 residues
around the hydrophobic center of each helix. Then these
hydrophobic moments are projected onto the plane of inter-
section of the hydrophobic centers. The degree of rotation
needed to point the end of hydrophobic vector 180 away from
the center of the protein is used for the individual rotation of the
helices. This is pointed outward from the center of the xy
positions of the seven helices. The optimized helices of the
5-HT2B receptor from Cartesian neutral dynamics were rotated
by Eisenberg or octanol scale.
1.6. MembEnsemb. To select the initial orientation of the side
chains we use a Monte Carlo procedure. Using SCREAM22 for
selecting the side chain conformation considerably improves the
accuracy in comparing different rotations, and we have now
eliminated the ROTMIN step, replacing ROTSCAN with ROT-
SCREAM, and now the scan needs to only be in increments of 30,
rather than 5. All helices are rotated by 30 increments while
reassigning the side chain conformation by SCREAM method.22
Hydrophobicity penalty and interhelical E scan are performed to
maximize the best orientation of each helix and the side chain. For
the optimization of rotational orientation of the helices, each helix is
rotated through a grid of rotational angles while reassigning the
side chain conformation by SCREAM method.
1.7. Combinatorial Set using MembEnsemb. The combina-
torial sets lead to an ensemble (3-10) of packed bundles, each of
which we may use for docking candidate agonists and antago-
nists. Our working hypothesis is that GPCRs may sample three
or four (or more) packings of the helices during their dynamics as
they interact with agonists, antagonists, inverse agonists, or
modulators. By determining the properties for each of the
structures in this ensemble, we expect to obtain a better under-
standing of which structures might play a role in the various
processes of the GPCRs (some might be more favorable for
dimers). This systematic search over a grid of rotational angles
and translational distances is important because there are likely to
be substantial E barriers between some of the local minima,
which MD simulations may not find all of them.
1.8. BiHelix and CombiHelix. The top1 of the hHT2BR from
MembEnsemb was used for running BiHelix and CombiHelix.
To find a diverse ensemble of low E packing of the TM helices
and to validate the current hHT2B structure, we started with the
MembEnsemb structure and rotated independently 12 helix pairs
(H1-H2, H1-H7, H2-H3, H2-H4, H2-H7, H3-H4, H3-
H5, H3-H6, H3-H7, H4-H5, H5-H6, and H6-H7) in 30
increments through full a 360 (12 rotations in each helix),
leading to explicit 1728 (12  12  12) bundle configurations.
For each of these theoretical 35 million TM bundle configura-
tions, the pair E which was indicated in details in Table S1,
Supporting Information, was calculated.
In the combinatorial set, the best 100 structures were opti-
mized, all side chains using SCREAM calculated the polar
interhelical interaction E ignoring side chain-side chain EvdW
or all vdW E, or internal E, total interhelical interaction E, and the
membrane solvation E (MembSolE), ordered by total E, total
interhelical interaction E, and MembSolE.
The CombiHelix results for best 10 are shown in Table 1. The
current structure with all 0 angles for each helix ranked as
number 1. The second low-lying structure rotated -30 antic-
lockwise way for TM4 from the extracellular side. The third one
showed a single rotation of TM6 by 30. In addition to the
rotation of TM6 by 30, the fourth one showed an additional-
30 rotation of TM7 which revealed in the fifth case. All other
helices, TMs 1-3 and 5 showed 0 structure as the lowest-lying
one. Thus the best angles within best 5 are: TM1 = 0, TM2 = 0,
TM3 = 0; TM4 = 0 and -30, TM5 = 0, TM6 = 0 and 30, and
TM7 = 0 and -30.
The 0 case for each helix has the lowest E, validating that the
current model is correctly predicted through MembEnsemb
procedure. We believe the other low-lying packings of the helices
may play a role in binding of agonists and/or in activation.
The description of BiHelix energies is the BiHelx pair energy
(BiHelE) is the sum of the SCRAEM energies from all 12 pairs
for each of the 127 7-helix conformations, properly corrected for
overcounting of the intrahelix interactions.
BiHelE ¼ SumHiHj ¼ Totintra-ii þ Totintra-jj þ Totinter-ij
where Totintraii is the total intrahelical energy of Helix i in the ij
pair, Totintrajj is the total intrahelical energy of Helix j in ij pair,
Totinterij is the total interhelical energy between helices i and j,
and TotinterH-ij is the interhelical hydrogen-bond energy between
helices i and j. Interhelical H-bond energy (InterHB) is the sum
of all interhelical H-bond energies between all 12 pairs of helices.
The description of CombiHelix energies is for each of the
seven-helix conformations selected from the BiHelix analysis we
built full seven-helix bundle, scream all seven helixes simulta-
neously, and evaluated the energy, ScreamTot. In addition, we
evaluated the membrane solvation free energy (MembSolE, Es)
using a multidielectric (80|7|2|7|80) implicit membrane model
of the total solvation free energy change associated with transfer
of protein from implicit bulk water.
ScreamTot ¼ Totfm þ Totscsc þ intern
where Totfm is intern þ Vfsc þ VTotfm þ CHTotfm; intern is the
valence energy terms of the SCREAMed residues; Vfsc is the vdW
energy between SCREAMed residue side chains and fixed residue
side chains; VTotfm is Vfsc þ vdW energy between SCREAMed
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residue side chains and all backbones; andCHTotfm is Coulomb plus
HB energy between fixed residues and SCREAMed residue side
chains. Totscsc is Vscsc þ CHscsc, where Vscsc is the vdW energy
among SCREAMed residue side chains; CHscsc is the Coulomb and
HB energy among SCREAMed residue side chains; MembSolE is
Es =E1-E2þ E3;E1 is the polar solvation energy of the protein in a
multidielectric (80|7|2|7|80) implicit membrane; E2is the polar
solvation energy of the protein in implicit bulk water; and E3is the
nonpolar solvation free energy change corresponding to transfer
of protein from implicit bulk water to multidielectric (80|7|2|7|
80) implicit membrane, approximated as γ  Lipid exposed
solvent accessible surface area.
2. Generation of Loops by CCBB Loop Builder. Loops were
predicted by a newCCBB loop builder using theCCBBMonteCarlo
method developed for predicting free energies of polymer chains
combined with restraint generic protein algorithm41 for handling the
constraint of terminating the loop on the adjacent TM domains.
The disulfide bond between C128 and C207 was constructed.
The final structure was optimized without any constraints. To
save the simulation time in explicit membrane and water,
truncated intracellular loop (IL) 3, from A247 to V313, which
was far away from the binding site that was used.
To provide initial loop structures for other low-lying packing
structures, the loops of three EL and three IL parts were
connected into four other TM structures. Connection parts were
minimized with trans-amide torsional constraints and backbone
freeze atoms at the R-helix structure.
To check the quality of the model, the main chain parameters
(Ramachandron plot quality assessment, peptide bond planarity,
measure of bad nonbonded interactions, R carbon tetrahedral
distortion, and HB energies) and the side chain parameters (the
standard deviation angle of χ-a gauche minus, χ-1 trans, χ-1
gauche plus, and χ-2 trans angle) used Procheck program to
reveal statistically better or reasonable results.
3. Docking Study. 3.1. GenMSCDock. The putative binding
sites for agonists and antagonists of the hHT2BRs were deter-
mined using GenMSCDock. GenMSCDock was the next gen-
eration of HierDock42andMSCDock,43 but many improvements
have also been made. MSCDock was successfully applied to
mMrgC1120 and hHT2C3 receptors, as described previously. This
procedure solved the problem of allowing bulky residues and bulky
ligands to accommodate each other. The validation of Gen-
MSCDock has been described previously.44We docked the antago-
nist, ZM241385, to the crystal structure of the hAA2AR (PDB ID:
3eml). Our best predicted structure (best cavity energy) is 0.80 Å
RMSD from the X-ray structure. The largest deviation was at the
phenoxy ring exposed toward EL 2 and 3 due to the three waters
surrounding the phenoxy ring in the X-ray complexes.
GenMSCDock sampled a complete set of configurations for
each conformation of the ligand. This leads to a hierarchy of
families with a specified range of diversities, allowing the best
to be selected at a coarse level by evaluating energies of family
heads. This also leads to an ensemble of the best diversity
families that are used for higher-level calculations. The steps in
GenMSCDock include bulky residue alanination, diversity
finder, Voronoi reclustering, side chain refinement, and neu-
tralization:
(1) Bulky residue alanination: To accommodate various
orientations of the ligands, all bulky residues (Phe,
Trp, Tyr, Val, Ile, and Leu) were replaced by Ala.
(2) Diversity finder: A critical part of GenMSCDock is to
sample all binding configurations in all potential binding
sites and to group the results into families of related
structures allowing whole family to be rejected when the
parent of a family is weakly bound. The GenMSCDock
method does two rounds, one to ensure completeness
and the other to enrich the better families. Based on our
experiences, a larger diversity parameter of 1.2-1.4 Å in
the completeness step generates ∼2500 families. To
achieve an average of 6 children in each family, we resort
to obtain 0.6 Å families in the enrichment step.
(3) Voronoi reclustering: As an enrichment step, Voronoi
clustering fractionizes to ensure that each family has the
closest children within it. We find that with a 0.6 Å
diversity threshold all members of a family minimize to
essentially the same structure.
(4) Side chain refinement: For each of the 10% low E
conformation from Voronoi clusters, we dealaninize
the binding site with the ligand present using the
SCREAM procedure.22 SCREAM finds the optimum
side chain conformations for the bulky residues compa-
tible with each ligand configuration. After SCREAM, a
short full complexminimization is performed. Total 50%
subset from our hierarchy was selected for further steps.
(5) Neutralization of charged groups: To remove the sensitivity
of counterions distant from the active site, charged residues
and ligands are modified by protonating or deprotonated.
This leads to a smoother electrostatic potential and smaller
solvation E difference in the binding site.
(6) Relaxation: For each of the 50% ligand side chain
combination, we now define a unified binding site and
thenminimize the atoms in the binding pocket. Then for
another 50% subset, we minimize the structure for the
full ligand-protein complex and pick a subset of 50%
for annealing within 5 Å of the binding site.
(7) Scoring E: GenMSCDock allows at each step for a
percentage of the protein-ligand complexes to be elimi-
nated based on E criteria including continuum solvent
corrections. This improved procedure is now being
automated to increase the number of ligands for practical
considerations. In each step, the complex was scored
using the following different E criteria.
E scoring:
• UnifiedCav (Unified cavity): the E from cavity analysis
where all residues in the unified cavity analysis contribute
to the E.
• LocalCav (Local cavity): the normal version of cavity
analysis where only residues within the local 5.0 Å binding
cavity contribute to the E.
• Total: the MPSim E of the total complex (all atoms
movable).
• FullSol (Full solvation E): the binding E with solvation for
the complex, protein, and ligand. BE = (complexvacþ com-
plexsolv)-[(proteinvacþproteinsolv)þ (ligandvacþ ligandsolv)].
• PartialSol (Partial salvation E): the binding E with solva-
tion only for the ligand. BE = complexvac - [proteinvac þ
(ligandvac þ ligandsolv)].
• Interaction: the MPSim interaction E between the protein
and ligand (protein fixed, ligand movable).
3.2. Ensemble Docking. The best ligand conformation from
GenMSCDock matched several low-lying packing structures and
relaxed the binding site to maximize the interaction through the
following sequential steps, BindsiteScream (SCREAM the 5 Å
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binding site compatible with each ligand configuration), Bindsi-
teMinimize (the 5 Å binding site minimization), ComplexMini-
mize (full complex minimization), BindsiteAnneal (binding site
annealing), and Neutralize including full complex minimization.
4. MD Simulations in Explicit Membrane and Water. To
construct the periodic cell (73 70 71 Å) for the MD simula-
tions, the predicted structures of apo-hHT2BR, agonist (5-HT)-
hHT2BR, and antagonist (2)-hHT2BRwere each independently
embedded in the center of a square periodic lipid bilayer
consisting of 100 palmitoyloleoyl phosphatidylcholine (POPC)
molecules and solvated with 6689 water molecules. We used the
CHARMM22 force field parameters for the protein, the TIP3
model for water,38 and the CHARMM27 force field parameters
for the lipids.45 Quantum charges from DFT/6311G** method
were used for these ligands.
To compensate for the net charge of the protein and ligand,
two waters for the apo-hHT2BR/the antagonist-bound
hHT2BR, three waters for the agonist-bound hHT2BR, and
seven waters for the antagonist-bound hHT2CR were replaced
by chloride ions to attain a zero net charge for the entire system.
These systems contains 38 051 atoms (apo-hHT2BR), 38 977
atoms (5-HT-hHT2BR), 38 672 atoms (antagonist 1-hHT2BR,
38 818 atoms (antagonist 2-hHT2BR), and 38 025 atoms
(antagonist 1-hHT2CR and antagonist 2-hHT2CR).
The process was first to minimize the water, ion, and lipid
bilayer while keeping the protein and ligand fixed. This was
followed by an all-atom conjugate gradient minimization of the
entire system for 1000 steps. After this minimization, we carried
out 500 ps of MD simulations for equilibration with 1 fs time
steps, followed by 1000 steps of minimization of the full system.
Langevin dynamics was used for temperature control with the
thermostat set at 310 K. The Nose-Hoover Langevin piston
pressure control was used to control fluctuations in the barostat,
which was set at a pressure of 1 bar. Here the periodic cell was
constrained to remain orthorhombic, but the cell parameters
were allowed to vary. A dielectric constant of 1 was used for the
electrostatic interactions, which were calculated by using the
particle mesh Ewald method.46 The grid in the x, y, and z
directions used for the particle mesh Ewald method was set at
72, 75, and 81 points, respectively. Every 10 ps a snapshot was
written to the trajectory file for subsequent analysis.
Seven independent 1 ns MD simulations were carried out by
using the program NAMD 2.6 for all minimization and MD
runs.47 Three further 10 ns simulations were done for apo,
agonist-bound, and antagonist 2-bound hHT2BR.
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